Literature DB >> 2448025

Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content.

S Schröder1, W Böcker, H Baisch, C G Bürk, H Arps, I Meiners, H Kastendieck, P U Heitz, G Klöppel.   

Abstract

Patients with medullary thyroid carcinomas (MTC) were analyzed according to age, sex, and tumor stage. In addition, the MTC were screened for the predominant histologic pattern, immunocytochemical spectrum (60 tumors), and DNA content (DNA cytophotometry and DNA flow cytometry, 25 tumors). These findings were correlated with follow-up data available for 45 of these patients. Forty-eight percent of the tumors revealed a polygonal cell pattern, whereas 22% showed spindle-cell predominance. All tumors contained cytokeratin, chromogranin A, and calcitonin (CT). Calcitonin gene-related peptide (CGRP) was present in 92%, carcinoembryonic antigen (CEA) in 77%, neuron-specific enolase (NSE) in 75%, and vimentin in 53% of cases. Positivity for neurotensin, somatostatin, neurofilaments, bombesin, and alpha human chorionic gonadotropin (a-hCG) and serotonin ranged between 3% and 27%. All MTC were negative for substance P, adrenocorticotropic hormone (ACTH), thyroglobulin (TG), or S-100 protein. Local recurrences and regional lymph node metastases revealed identical staining patterns as the primaries. Prognosis of MTC was found not to be related to histologic features (dominant architectural pattern, cellular shape, presence of amyloid deposits) or immunocytochemical pattern. Instead, survival was significantly correlated to age, sex, and stage of disease. The best prognosis was seen in women younger than 40 years and revealing an early stage of disease. DNA measurements added valuable information in assessing the prognosis of MTC.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2448025     DOI: 10.1002/1097-0142(19880215)61:4<806::aid-cncr2820610428>3.0.co;2-g

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  [DNA cytophotometry in pathology and surgery].

Authors:  M Dietel
Journal:  Langenbecks Arch Chir       Date:  1992

2.  Medullary thyroid carcinoma: multivariate analysis of prognostic factors influencing survival.

Authors:  Isabel Peixoto Callejo; José Américo Brito; Carlos Manuel Zagalo; Jorge Rosa Santos
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

3.  Adrenomedullary hyperplasia and phaeochromocytoma. DNA cytophotometric findings in 47 cases.

Authors:  B C Padberg; E Garbe; E Achilles; H Dralle; M Bressel; S Schröder
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 4.  Intermediate filaments in the nervous system: implications in cancer.

Authors:  C L Ho; R K Liem
Journal:  Cancer Metastasis Rev       Date:  1996-12       Impact factor: 9.264

Review 5.  The utility of some modern techniques in understanding thyroid pathology.

Authors:  Virginia A LiVoisi
Journal:  Endocr Pathol       Date:  1990-06       Impact factor: 3.943

6.  Fatal sporadic medullary carcinoma of the thyroid.

Authors:  H Ruben Harach; Ulla Bergholm
Journal:  Endocr Pathol       Date:  1993-03       Impact factor: 3.943

Review 7.  The study of endocrine tumors by flow and image cytometry.

Authors:  Ingrid Zbieranowski; David Murray
Journal:  Endocr Pathol       Date:  1992-06       Impact factor: 3.943

8.  Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid gland.

Authors:  S Schröder; W Schwarz; W Rehpenning; H Dralle; V Bay; W Böcker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

9.  Markov model-based estimation of individual survival probability for medullary thyroid cancer patients.

Authors:  Olga Esik; Gábor Tusnády; Lajos Trón; András Boér; Zoltán Szentirmay; István Szabolcs; Károly Rácz; Erzsébet Lengyel; Judit Székely; Miklós Kásler
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

10.  Relationship of CD15 immunoreactivity and prognosis in sporadic medullary thyroid carcinoma.

Authors:  N Neuhold; F Längle; M Gnant; U Hollenstein; B Niederle
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.